Ocular Therapeutix(US:OCUL) Globenewswire·2026-02-05 12:00Core Insights - Ocular Therapeutix is preparing to present topline results from the SOL-1 Phase 3 superiority trial for AXPAXLI™ in wet AMD at the 49 Macula Society Annual Meeting scheduled for February 25-28, 2026 [1][3] - The company plans to submit a New Drug Application (NDA) for AXPAXLI based on the SOL-1 52-week data, contingent on positive results and discussions with the FDA [1][3] - The SOL-R Phase 3 non-inferiority trial has completed randomization of 631 subjects, with topline results expected in Q1 2027 [1][3] - Ocular has a cash balance of $737.1 million as of December 31, 2025, which is projected to support operations into 2028 [1][5] Business Highlights - The SOL-1 trial is designed to evaluate the safety and efficacy of AXPAXLI in treating wet AMD, with a primary endpoint focused on maintaining visual acuity [3][16] - The SOL-R trial aims to demonstrate non-inferiority compared to aflibercept, with a primary endpoint at Week 56 [3][19] - The HELIOS-3 trial for diabetic retinopathy is currently underway, with a focus on subjects with moderately severe to severe non-proliferative diabetic retinopathy [4][24] Financial Performance - Total net revenue for Q4 2025 was $13.3 million, a decrease of 22.4% from $17.1 million in Q4 2024 [6] - For the full year 2025, total net revenue was $52.0 million, down 18.5% from $63.7 million in 2024 [6] - Research and development expenses increased to $50.8 million in Q4 2025 from $41.0 million in Q4 2024, reflecting ongoing clinical trial costs [7] - The company reported a net loss of $(64.7) million for Q4 2025, consistent with a net loss of $(48.4) million in Q4 2024 [10] Future Developments - The SOL-X open-label extension trial is expected to begin in Q2 2026, allowing subjects from SOL-1 and SOL-R to enroll for additional safety follow-up [3][21] - The company raised approximately $475 million from an equity offering in September 2025, with net proceeds supporting operations into 2028 [4]